Maximizing Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer.

Slides:

Advertisements

Similar presentations

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Advertisements

Advances and Emerging Therapy for Lung Cancer

William J. Gradishar MD, FACP Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center For Women's Cancer Care Robert H. Lurie Comprehensive.

HIGHLIGHTS IN THE MANAGEMENT OF BREAST CANCER

ESMO 2011 Breast Cancer Trastuzumab in untreated MBC Authors: CARE Faculty (Drs. Anil Joy and Sunil Verma) Date posted: October.

Transplant Creations1 Treatment & Transplant Program to improve disease outcome Transplant Creations Marlies Van Hoef.

MBCG Project Primary Results MEDICALSURVEYS-17 RESEARCH GROUP IN COLLABORATION WITH THE EASO.

Breast cancer affects 1 in 8 women during their lives. 1 Population Statistics.

PHASE II RANDOMIZED STUDY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB PLUS DOCETAXEL IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 – POSITIVE.

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard.

Product Pipeline Neratinib across the breast cancer therapy spectrum

Slamon D et al. SABCS 2009;Abstract 62.

A. Schema of NSABP B-27 trial comparing neoadjuvant AC to neoadjuvant AC followed by neoadjuvant docetaxel and to neoadjuvant AC followed by adjuvant docetaxel.

Perez EA et al. SABCS 2009;Abstract 80.

Intention-to-treat population

Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer

The Nurse View: Management of Pancreatic Cancer

New Paradigms for HER2-Positive Early Breast Cancer: Implications and Application.

Product Pipeline Neratinib across the breast cancer therapy spectrum

Metastatic HER2+ Breast Cancer: Resistance

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.

Diabetic Dyslipidemia in Practice

ASCO 2018 Tracing Tucatinib's Role in HER2+ Breast Cancer Treatment Published: Thursday, Jun 14, ESTUDOS DE FASE I: TUCATINIBE + TRASTUZUMABE +

NOACs for Cancer-Associated Thrombosis:

The Current Status of Neoadjuvant Therapy in HER2-Positive Breast Cancer.

Neoadjuvant Therapy for HER2-Positive Breast Cancer

Updates on the Use of Adjuvant Therapy in HER2-Positive Breast Cancer

Her2-positive breast cancer: updating current best practice

Progression After Cancer Immunotherapy in Advanced NSCLC

سرطان الثدي Breast Cancer

Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.

Neoadjuvant Therapy in HER2-Positive Breast Cancer

Clinical Considerations in Evidence-based Management of GIST

Jones SE et al. SABCS 2009;Abstract 5082.

Activity Goals. Activity Goals Case Presentation.

Managing gBRCA-Positive Metastatic Breast Cancer

Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients Breast Care 2016;11: DOI: / Fig. 1. Strategies.

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

Treatment of HR+ Breast Cancer: A Clinical Update

Forming Effective Individualized Treatment Plans for Patients With Low-Risk MDS.

Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011

Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.

Optimizing Neoadjuvant Treatment for Primary Breast Cancer

Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.

Examining the Latest Evidence in PAH

Mutational Testing to Select Novel Targeted Therapies in AML

Case 1: Introduction. Adjuvant Therapy: Should It Be Considered in Older Patients With NSCLC?

Program Goals Basal Cell Cancer Basal Cell Cancer: Beyond Surgery.

Best Practices in Lymph Node Mapping and Localization: Melanoma

The Road to Quality Improvement in HER2-Positive Breast Cancer

Implications of Emerging Treatments for Beta-Thalassemia

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

New ELN Recommendations

Product Pipeline Neratinib across the breast cancer therapy spectrum

Incorporating Prostacyclins Into Practice

Challenges in LA SCCHN.

Novel Concepts in the Management of RCC

From Adjuvant to Metastatic in Melanoma

Targeting the Androgen Pathway: Current Best Practice and Future Directions.

Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer.

Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer

Arlene Chan, Marc Buyse, Bin Yao The Lancet Oncology

Clinical Considerations in Evidence-based Management of GIST

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Pulmonary Arterial Hypertension and Hospitalizations

Comprehensive Acne Management

Uncovering the Right Sequence

Presentation transcript:

Maximizing Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer

Introduction to HER2+ Early Breast Cancer

Newer HER2-Targeted Agents Used in Early Breast Cancer: Pertuzumab

Use of Pertuzumab in Adjuvant Setting

Considerations with Pertuzumab

Newer HER2-Targeted Agents Used in Early Breast Cancer: Neratinib

Subset Analysis in ExteNET Trial

Neratinib-Associated Diarrhea

Newer HER2-Targeted Agents Used in Early Breast Cancer: Ado-Trastuzumab Emtansine (T-DM1)

Toxicities Associated with T-DM1

Options for High Risk Patients With HER2+ Early BC

Is De-Escalating Treatment Ever an Option?

Incorporating Novel Agents into Practice: Adjuvant Therapy Guidelines

Patient Education Tips with HER2-Targeted Therapies for Early BC

Managing Side Effects Associated With HER2-Targeted Agents

Implementing a Patient-Centered Approach

Multidisciplinary Team Involved in Care of Patients With Higher-Risk Early Breast Cancer

Management and Education for Patients Receiving HER2-Targeted Therapies for Early BC

Moving Towards Personalized Therapy for HER2+ Breast Cancer

Abbreviations